Skip to Content
Merck
All Photos(3)

Documents

SML0005

Sigma-Aldrich

Cerivastatin sodium salt hydrate

≥98% (HPLC)

Synonym(s):

(3R,5S,6E)-7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid sodium salt hydrate, Rivastatin hydrate

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C26H33FNNaO5 · xH2O
CAS Number:
143201-11-0
Molecular Weight:
481.53 (anhydrous basis)
MDL number:
MFCD20488047
UNSPSC Code:
12352200
PubChem Substance ID:
329825082
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +18 to +26° in ethanol

storage condition

desiccated

color

white to tan

solubility

H2O: ≥5 mg/mL

originator

Bayer

storage temp.

2-8°C

SMILES string

O.[Na+].COCc1c(nc(C(C)C)c(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)c1-c2ccc(F)cc2)C(C)C

InChI

1S/C26H34FNO5.Na.H2O/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4;;/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32);;1H2/q;+1;/p-1/b11-10+;;/t19-,20-;;/m1../s1

InChI key

NJHMEKXCHXHQPP-PZLZTSNUSA-M

General description

Cerivastatin sodium salt hydrate belongs to the statin class of lipid lowering agents. It helps in decreasing MAP kinase activation, blocking AP-1 (activator protein-1) and NF-kB (nuclear factor-kB ) binding activity, inhibiting inflammatory responses and ameliorated renal damage. It also lowers cholesterol. It is metabolized by cytochrome P450 (CYP)3A4 and (CYP)2C8. Cerivastatin sodium salt hydrate is linked to rhabdomyolysis.

Application

Cerivastatin sodium salt hydrate has been used as a supplement in cell culture.
Cerivastatin sodium salt hydrate may be used in cell signaling studies.

Biochem/physiol Actions

Accumulated macrophages in atherosclerotic plaques result in plaque rupture and thrombus formation. Cerivastatin suppresses the growth of macrophages and decreases the expression of matrix metalloproteinases and tissue factor molecules, thus reduces acute coronary events.
Cerivastatin sodium is an HMG-CoA reductase inhibitor. HMG-CoA is a key enzyme in the production of cholesterol.

Features and Benefits

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M A Crouch
American family physician, 63(2), 309-320 (2001-02-24)
Primary and secondary prevention trials have shown that use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) to lower an elevated low-density lipoprotein cholesterol level can substantially reduce coronary events and death from coronary heart disease. In 1987
GTSE1: a novel TEAD4-E2F1 target gene involved in cell protrusions formation in triple-negative breast cancer cell models
Stelitano D, etal.
Oncotarget, 8(40), 67422-67422 (2017)
A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin
Ishikawa C, et al.
Journal of Human Genetics, 49(10), 582-585 (2004)
M Aikawa et al.
Circulation, 103(2), 276-283 (2001-02-24)
Unstable atherosclerotic plaques that cause acute coronary events usually contain abundant macrophages expressing matrix metalloproteinases (MMPs) and tissue factor (TF), molecules that probably contribute to plaque rupture and subsequent thrombus formation. Lipid lowering with HMG-CoA reductase inhibitors reduces acute coronary
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
Mazzu AL, et al.
Clinical Pharmacology and Therapeutics, 68(4), 391-400 (2000)
View All Related Papers

Articles

Antilipemic Agents

Randomized controlled clinical studies have suggested 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both primary and secondary prevention of cardiovascular disease (CVD) events.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service